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The prevalence of cystic fibrosis-related diabetes (CFRD) and glucose intolerance (IGT) has risen dramatically over the past 20 years as
survival has increased for people with cystic fibrosis (CF). Diabetes is primarily caused by pancreatic damage, which reduces insulin
secretion, but glucose tolerance is also modified by factors that alter insulin resistance, such as intercurrent illness and infection. CFRD not
only causes the symptoms and micro and macrovascular complications seen in type 1 and type 2 diabetes in the general population, but also
is associated with accelerated pulmonary decline and increased mortality. Pulmonary effects are seen some years before the diagnosis of
CFRD, implying that impaired glucose tolerance may be detrimental.
Current practice is to screen for changes in glucose tolerance by regular measurement of fasting blood glucose, by oral glucose tolerance
test or a combination of these approaches with symptom review and measurement of HbA1C. Treatment is clearly indicated for those with
CFRD and fasting hyperglycaemia to control symptoms and reduce complications. As nutrition is critical in people with CF to maintain body
mass and lung function, blood glucose should be controlled in CFRD by adjusting insulin doses to the requirements of adequate food intake
and not by calorie restriction. It is less clear whether blood glucose control will have clinical benefits in the management of patients with
CFRD without fasting hyperglycaemia or with impaired glucose tolerance and further studies are required to establish the best treatment for
this patient group.
D 2004 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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Cystic fibrosis (CF) is the commonest lethal autosomal
recessive disorder in Caucasian populations, with an
incidence of 1 in 2500 live births [1]. Over 1000 unique
mutations have been described in the cystic fibrosis trans-
membrane conductance regulator gene, the commonest of
which is a deletion of phenylalanine in the amino acid
position 508. These mutations lead to defective production
of a protein called CF transmembrane conductance regulator
(CFTR) that functions as a cAMP-regulated chloride
channel. Impaired function of CFTR affects the trans-
epithelial transport of ions and water mainly in the cells of
the respiratory, gastrointestinal, hepatobiliary and reproduc-
tive systems. The common pathological finding in these
organs is accumulation of thick viscous secretions associa-
ted with progressive scarring and destruction.
Improved clinical care has led to a dramatic increase in
life expectancy for people with CF. In the 1950s, life
expectancy for people with CF was less than 1 year, whereas
in 2001 predicted survival for people on the Cystic Fibrosis
Foundation Patient Registry was 33.4 years [2]. As people
with CF live longer, glucose intolerance and cystic fibrosis-
related diabetes (CFRD) are becoming more common [2].
Pre-existing lung disease means the implications of deve-
loping diabetes for people with CF are very different from
those for people with type 1 and type 2 diabetes mellitus.
People with CF who develop diabetes experience acce-
lerated decline in CF clinical status and pulmonary function
[3–6], as well as having a higher mortality rate than those
without diabetes [3,7]. Understanding the pathogenesis and
optimal methods of diagnosis and treatment for CFRD istherefore important, not only to prevent the micro and
macrovascular complications associated with all forms of
diabetes mellitus, but also to prevent and treat deterioration
in pulmonary disease.2. Prevalence OF CFRD
The average age of onset of CFRD in the 1990s was 19
to 21 years [8,9]. It is therefore only within the last 20
years that a significant proportion of people with CF has
survived long enough to develop CFRD. The reported
prevalence figures for CFRD over the last 50 years are
difficult to compare between decades as the criteria
employed for defining CFRD have gradually evolved over
this time.
The Cystic Fibrosis Foundation Patient Registry, which
collects information from 22,732 people with CF of all ages
in the United States and Canada, has shown that the
diagnoses of glucose intolerance and diabetes in CF are
becoming more prevalent (Fig. 1) [2]. The most recent
estimate in 2002 showed that 12% had diagnoses of CFRD
and glucose intolerance based on physician reports [2]. In
centres where annual oral glucose tolerance testing is
routinely performed, CFRD and glucose intolerance are
detected more frequently. Of 311 people with CF who
underwent an OGTT in Denmark in 1994, 14.7% were
diabetic, while a further 13.7% had IGT [9]. 11% of people
with CF over the age of 5 years in Minnesota had CFRD,
while 17% had CFRD without FH [10]. The prevalence of
CFRD increases with age (Fig. 2) [11], with more than 25%
of people over the age of 20 receiving a diagnosis of CFRD
Fig. 1. Graph demonstrating prevalence of CFRD and glucose intolerance over the last 14 years in people registered on the Cystic Fibrosis Foundation Patient
Registry.
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becoming longer each year, the proportion with abnormal
glucose tolerance is likely to continue to increase.3. Pathophysiology of CFRD
All forms of diabetes are characterised by chronic
hyperglycaemia resulting from defects in insulin secretion,Fig. 2. The percentage prevalence of CFRD within age groups in people
with CF attending the clinic at University of Minnesota in 1996. People
with CFRD include those who required long-term insulin to prevent FH and
those who intermittently required insulin during periods of stress (adapted
from Moran et al. [11]).action or both. CFRD is distinct from both type 1 and type
2 diabetes in its pathogenesis. Type 1 diabetes is typified
by the absence of insulin due to autoimmune destruction of
the h-cells within the islets of Langerhan. Type 2 diabetes
is a combination of the effects of relative insulin defi-
ciency compared to need, and increased insulin resistance,
where the tissues are unable to respond to insulin. The
American Diabetes Association places CFRD in the
category of bother specific types—diseases of the exocrine
pancreasQ [12].
The aetiology of CFRD is complex and the mechanisms
leading to the development of CFRD are not fully under-
stood. A possible sequence of events that could lead to
glucose intolerance is proposed in Fig. 3.
3.1. Reduced insulin secretion
3.1.1. Structural abnormalities of the endocrine pancreas
The pancreas is histologically abnormal in almost all
people with CF. Many investigators have proposed that
pancreatic damage arises from changes in the composition
of pancreatic secretions secondary to CFTR mutations.
Abnormal expression of CFTR in intralobular duct cells and
pancreatic centroacinar cells appears to cause reduced
chloride and bicarbonate ion secretion with reduced fluid
secretion into the pancreaticobiliary ducts [13,14]. Pancrea-
tic proteins including enzymes become concentrated within
the pancreatic ducts, causing protein precipitation and
ductal obstruction. A reduced intraluminal pH, resulting
from the reduction in bicarbonate secretion, may exacerbate
Fig. 3. Possible sequence of pathological events leading to abnormal glucose homeostasis in people with CF.
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causes interstitial oedema in the surrounding acinar tissue,
probably impairing blood flow within the pancreatic tissue
leading to ischaemic damage. Activated proteases and
lipases within the obstructed ducts may lead to autolysis
of the pancreas.
Post mortem studies of pancreatic morphology have
been performed in people with CF varying in age from
preterm infants to 32 years. These have confirmed a
spectrum of histological abnormalities, which become more
severe with increasing age. Even in infancy, there is a lack
of normal pancreatic maturation, with focal accumulation of
secretory material within the pancreatic ducts associated
with duct dilation [15,16]. In older people with CF there is
atrophy and fibrosis of the pancreatic acinar tissue with
reduction in the number of acini and replacement of
exocrine tissue with fatty infiltration [17,18]. Of importance
there is a significant reduction in the proportion of h-cells
within the residual islets from people with CFRD as
compared to those with normoglycaemia. The loss of
endocrine pancreatic tissue may contribute to the develop-
ment of CFRD [18,19].
Deposition of islet amyloid may contribute to impairment
of endocrine pancreatic function in people with CF. It is not
clear how islet amyloid is formed, but it appears to be
derived from amylin, a 37 amino acid polypeptide which is
normally produced by the h cells and co-packaged with
insulin. A high proportion of people with type 2 diabetes has
islet amyloid deposits, the extent of which increases with the
severity of diabetes. It has been proposed that increased
redox stress within the islets of people with type 2 diabetesmay promote unfolding of the native secondary structure of
h-cell derived amylin, which then may refold into the anti-
parallel crossed h-pleated sheet structure of islet amyloid
[20]. The role of islet amyloid in the development of cellular
damage or dysfunction remains unclear. Intracellular amy-
loid particles have been shown to be cytotoxic to h-cells,
inducing apoptosis by membrane disruption [21]. Progres-
sive accumulation of extracellular islet amyloid may
increase the severity of diabetes by acting as a diffusion
barrier for insulin and glucose within the islet, thus reducing
the glucose sensing ability of islet cells and impairing
secretion of insulin. Couce et al. identified islet amyloid in
pancreases from 11 of 16 (69%) people with CFRD, 2 of 12
(17%) people with CF with borderline diabetes, and 0 of 13
of people with CF without diabetes [22]. Islet amyloid
deposition appears to be dependent on intracellular pH.
Hence CFTR mutations, which may alter intracellular pH,
could predispose to intracellular aggregation of islet
amyloid [23,24].
3.1.2. Functional evidence of endocrine pancreatic
insufficiency
Approximately 85% of people with CF exhibit signs
and symptoms of exocrine pancreatic insufficiency. There
is a strong association between exocrine pancreatic disease
and the development of CFRD [25]. Insulin secretion and
hormone responses are normally intact in people with CF
who have exocrine pancreatic sufficiency [26]. However,
the normal insulin response to oral glucose challenge is
compromised in people with exocrine pancreatic insuffi-
ciency, even in those with normal glucose tolerance.
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41% reduction in peak plasma insulin concentration in
response to oral glucose and a substantial delay in the time
to reach peak insulin concentration compared to healthy
controls (Fig. 4) [27]. In a second study, people with
pancreatic insufficiency had a delayed first phase C-peptide
response to oral glucose, although the total amount of
insulin secreted was normal [26]. Insulin secretion is
progressively reduced as pancreatic damage worsens and
glucose tolerance deteriorates. The time to reach peak
insulin concentration following oral glucose load was
increasingly delayed from 20–60 min in healthy volun-
teers, to 30–120 min in people with CF with NGT, 60–120
min in people with CF with IGT and 150 min in people
with CFRD (Fig. 4) [26]. In addition, the total quantity of
insulin secreted was reduced in people with CFRD [26,27].
Therefore since a rapid postprandial rise in glucose is
typically followed by a delayed but prolonged insulin
response, people may develop symptoms of both hyper and
hypoglycaemia [28].Fig. 4. Mean (a) plasma insulin and (b) glucose profiles following extended
oral glucose load in healthy controls (o, n=8) and in people with cystic
fibrosis with differing glycaemic status (normal glucose tolerance, .,
n=16; impaired glucose tolerance, E, n=6; diabetic glucose tolerance, n,
n=2). The 120-min cut-off time point for determining glycaemic status is
also shown (reproduced from Yung et al. [27]).3.1.3. Factors determining susceptibility to endocrine
pancreatic damage
Although the majority of people with CF develop
exocrine pancreatic damage, not all develop glucose
intolerance. A second aetiological factor may determine
individual risk of developing CFRD.
3.1.3.1. Genetic susceptibility. The clinical phenotype of
people with cystic fibrosis varies greatly and some studies
have linked phenotypic variability and severity of CF with
the type of genetic mutation causing the disease [25]. The
European Epidemiologic Registry of Cystic Fibrosis study
[25] analysed the link between different classes of
mutations carried and the severity of major disease
manifestations in 8693 patients. It demonstrated that people
homozygous for the milder Class IV mutations were less
likely to develop diabetes (only 1 of 65 patients) than those
homozygous for class II mutations, e.g. A¨F508 (22.1% of
1276 patients). People with Class IV disease are less likely
to develop pancreatic damage and exocrine insufficiency,
which may account for the low prevalence of CFRD in this
group.
No link has been found between the development of
CFRD and HLA alleles DR3, DR4, DR3/4 and HLA-DR2,
which are associated with type 1 diabetes in the general
population [29].
3.1.3.2. Autoimmune processes. In the general population
type 1 diabetes is caused by autoantibodies to islet h cells
which trigger cell-mediated immune destruction and insulin
deficiency. Formation of these antibodies may be triggered
by a viral infection, such as mumps, measles and coxsackie.
Islet cell antibodies are found in 85–90% of people with
type 1 diabetes at the time of diagnosis, but have rarely been
detected in the sera of people with CFRD [29–32]. Anti-
bodies to glutamic acid decarboxylase (GAD), an intra-
cellular protein which shares amino acid sequences with a
Coxsackie virus protein, also are present in people with type
1 diabetes. GAD autoantibodies were found by a single
group in 15 of 30 people with CF [33]. Whether these
antibodies cause h-cell damage and diabetes, or are formed
in response to the release of antigens during cellular injury
is currently unknown.
There is some evidence that serum antibody responses
to bacterial antigens are related to the development of
diabetes in people with CF. In retrospective longitudinal
studies, IgG antibodies to the Pseudomonas aeruginosa
antigen 60-kDa GroEL were measured in serum from pre-
diabetic and non-diabetic people with CF stored over 5–9
years [34]. 60-kDa GroEL IgG increased in both groups by
5–6% per year during the observation period, but increased
by 24.6% in the prediabetic group 3–12 months prior to
the onset of diabetes. The 60-kDa GroEL protein is a
member of a group of bacterial 60–65 kDa hsps peptides,
which induce diabetes in animal models [35,36]. This
immunological response to pulmonary infection could
Fig. 5. Mean values of FEV1, expressed as percent predicted for gender and
height (FEV1%), in people with CF with and without CFRD by age group
(adapted from Koch et al. [46]).
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diabetes.
3.2. Increased insulin resistance
Insulin resistance is the inability of insulin to produce
its usual biological actions at circulating concentrations
that are effective in normal subjects. It occurs when there
is impaired ability of insulin to stimulate glucose uptake
by skeletal muscle and/or suppress hepatic glucose
production.
The bgold-standardQ method for measuring insulin
resistance is the hyperinsulinaemic euglycaemic clamp
technique, which involves simultaneous infusion of insulin
and glucose. If endogenous hepatic glucose production is
completely inhibited by an infusion of insulin, then the
quantity of exogenous glucose required to maintain eugly-
caemia is a reflection of the net sensitivity of peripheral
tissues to insulin. This technique has been used to study the
role of increased peripheral insulin resistance in the
development of CFRD [37–42]. There is some evidence
that people with CFRD have increased insulin resistance
[38,41,42]. The findings are less clear in people with NGT
and IGT. Moran et al. [38] found normal insulin resistance
in people with NGT, but reduced peripheral insulin
resistance in people with IGT. Hardin et al. [41] found
increased insulin resistance in all CF people with NGT and
IGT. Several factors may explain the differences observed
between studies. First, the clinical status of the people
studied in these trials varied markedly, particularly in
respect to pulmonary function. Second, although the insulin
infusion rates used in the experiments were adequate to
suppress hepatic glucose production in people without CF,
hepatic glucose production was not completely suppressed
in people with CF [38] and insulin resistance may therefore
have been underestimated.
The molecular and cellular basis for insulin resistance is
not fully understood. Aetiological factors include decreased
numbers of insulin receptors, impaired post-receptor signal-
ing or impaired translocation of glucose transporters, which
mediate glucose uptake, to cell membranes. In CF altered
insulin resistance does not appear to be due to a reduction in
the number of insulin receptors, in fact the number of insulin
receptors are increased [43]. However, insulin binding to the
receptor is reduced [43,44]. In addition, translocation of the
glucose transporter GLUT4 to the plasma membrane is
reduced in people with CF [42].
People with CF are likely to have variable insulin
resistance dependent on their clinical status. During times
of illness cytokines (e.g. tumour necrosis factor-a, inter-
leukin-6) or corticosteroid administration can precipitate
hyperglycaemia by increasing insulin resistance. TNF-a
levels increase during periods of acute infection and are also
higher in people with worse clinical status [42]. TNF-a
affects insulin resistance by altering the phosphorylation
cascade of insulin signaling at the receptor level [45].Glucocortioid therapy reduces glucose uptake by skeletal
muscles and impairs insulin-mediated suppression of
hepatic glucose production. Insulin resistance may therefore
modulate the degree of glucose intolerance in some people
with CF.4. Clinical impact of CFRD
CFRD was initially thought to be mild and uncompli-
cated. However, it has become increasingly clear that CFRD
not only causes micro and macrovascular complications but
also has a negative impact on both pulmonary function and
mortality.
4.1. Impact of diabetes on survival in CF
People with CFRD have a higher mortality rate than
people with CF without diabetes. In a study of 448 people
with CF, fewer than 25% of people with diabetes survived to
age 30 years, whereas nearly 60% of people without
diabetes reached this age [3]. More recently the Cystic
Fibrosis Foundation Patient Registry reported that people
with CF and diabetes have a 6-fold greater mortality rate
than people without diabetes [7].
4.2. Effect of diabetes on pulmonary disease
4.2.1. Pulmonary function and CFRD
The presence of CFRD is tightly linked to poor lung
function. Cross-sectional analysis of 7566 people enrolled in
the European Epidemiologic Registry of Cystic Fibrosis
(ERCF) [46] found that FEV1% predicted was lower in
people with diabetes than in those without diabetes at all
ages (Fig. 5). For the whole group the mean FEV1%
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52% in people with CFRD. In addition, FVC% predicted
value and weight-for-age percentiles were lower in people
with CFRD than in people without diabetes in all age
groups.
4.2.2. Prediabetic decline in pulmonary function
The effect of the prediabetic state on clinical status of
people with CF is a much debated question. Several
retrospective studies have clearly demonstrated that the rate
of decline of FEV1 and FVC increases in people with
CF over a 2–4-year period prior to the diagnosis of CFRD
[3–6]. In one study the rate of decline in pulmonary function
was directly proportional to the severity of glucose
intolerance and the degree of insulin deficiency [5]. Lanng
et al. [4] found that FEV1 and FVC were already 20% and
10% lower in people with CFRD than in carefully matched
people with CF without diabetes 6 years prior to the onset of
diabetes. Insulin therapy in people with CFRD restored
FEV1 and FVC to the levels recorded at the start of the
6-year period. However, lung function remained reduced in
people with CFRD compared to non-diabetic controls.
4.3. Possible mechanisms of pulmonary decline in CFRD
The mechanisms leading to pulmonary decline in people
with CFRD are unclear, but it is most likely that the
combined effects of hyperglycaemia and insulin deficiency
are responsible.
4.3.1. Pulmonary effects of hyperglycaemia
Hyperglycaemia could cause the decline in pulmonary
function seen in people with CFRD directly, through
structural changes in lung tissue, or indirectly, by reducing
pulmonary defence against infection.
4.3.1.1. Direct pulmonary damage. Chronic abnormalities
in lung function have been identified in people with type 1
and type 2 diabetes mellitus without pre-existing lung
disease. In the Framingham Heart Study a diagnosis of
diabetes and a higher fasting blood glucose concentration
were both associated with lower than predicted spirometric
measures of pulmonary function [47]. FEV1 and FVC were
also consistently lower in diabetic individuals compared
with healthy individuals in the Copenhagen City Heart
Study (n=17,506), with a reduction of approximately 8% in
predicted values [48]. Hyperglycaemia is associated with
structural changes in lung tissue, which may account for the
development of abnormal pulmonary function in people
with diabetes. In an animal model, pulmonary changes were
observed in hamsters with streptozotocin-induced diabetes
after only 6 weeks of hyperglycaemia (23–25 mmol/l)
[49,50]. The pulmonary capillary endothelium became full
of plasmalemmal vesicles, alveoli collapsed and the lung
interstitium enlarged. In human subjects autopsy studies
have shown lungs from diabetic subjects to be abnormal,with thickened alveolar epithelial and pulmonary capillary
basal laminae [51]. Hyperglycaemia may cause pulmonary
damage by a number of mechanisms including overpro-
duction of superoxide molecules, increased production of
advanced glycation end products and changes in inflamma-
tory mediators. The combined effect of these processes is
cellular stress and damage, which could contribute to
decline in pulmonary function in people with CFRD.
4.3.1.2. Increased predisposition to infection. Pulmonary
infections are more common and have a worse prognosis in
people with type 1 and type 2 diabetes than in those without
diabetes [52–54]. Hyperglycaemia may have local and
systemic effects, which reduce pulmonary defence against
infection. Systemic neutrophil phagocytic activity and
chemokinesis are impaired by hyperglycaemia but function
can be restored by rigorous control of blood glucose [55].
Hyperglycaemia reversibly impairs mitogen stimulated
proliferation of lymphocytes [56] and causes non-enzymatic
glycosylation of immunoglobulins after only a few hours,
sufficient to cause impairment of function [57]. The function
of innate immune proteins such as collectins is also reduced
by glycosylation. Hyperglycaemic diabetic mice were less
able to resist pulmonary replication of collectin-sensitive
viruses than their non-diabetic counterparts [58]. There are
no direct studies of the effect of hyperglycaemia on
pulmonary defence in people with CFRD, however treat-
ment with insulin reduced the percentage of sputum cultures
positive for Streptococcus pneumoniae and Haemophilus
influenzae from people with CFRD [59].
4.3.2. Pulmonary effects of insulin deficiency
In type 1 diabetes, insulin deficiency has been associated
with significant reduction in inspiratory muscle and
diaphragmatic strength compared to healthy controls leading
to impaired pulmonary function [60]. Insulin is an anabolic
hormone that is critical in the regulation of protein
metabolism [61]. Whole body protein balance cycles
between periods of protein synthesis and breakdown. Post-
prandial insulin secretion normally causes a dose-dependent
suppression of protein breakdown. People with CF, who are
not acutely ill, have both increased protein synthesis and
breakdown, resulting in balanced whole body turnover [62].
However, when insulin secretion is decreased or insulin
resistance is increased the suppressive effect of insulin on
protein breakdown is reduced, resulting in net protein
catabolism [63]; therefore negative protein balance may
contribute to increased morbidity and mortality. Improved
nutritional status [64] and reversal of protein catabolism
stabilises pulmonary function [65,66].
4.4. Vascular complications of CFRD
4.4.1. Microvascular complications
In the general population, microvascular complications
of diabetes are determined by the duration of diabetes, the
Table 1
Categories of glucose tolerance in people with CF defined by an oral
glucose tolerance test [7]
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undetermined factors. Background retinopathy is unusual
before diabetes has been present for 5 years and the
incidence of nephropathy peaks 15–16 years after the onset
of diabetes. People with CF develop diabetes in the second
and third decade of life, and have only recently survived
long enough to develop diabetic complications. However,
reports of microvascular disease in CFRD are increasing.
In three separate small cross-sectional studies the
prevalence of diabetic retinopathy in people with CFRD
was found to be 15.8%, 5% and 16% [9,67,68]. In case
reports and cross-sectional studies of people with CFRD
who had retinopathy, all were adults (age 27 (18–35) years
(median (interquartile range)) and had developed CFRD for
12 (3–23) years prior to the diagnosis of retinopathy [9,69–
72]. The severity of retinal defects ranged from mild
background retinopathy to proliferative retinopathy, vitreous
haemorrhages and cataract formation. In almost all these
cases either raised HbA1C values or high random glucose
levels suggested poor long-term glycaemic control.
Diabetic nephropathy has been reported in 11 people
with CF [9,69–73]. In the majority of people, nephropathy
developed over 10 years after the diagnosis of CFRD was
made (12 (1–24) years). In four people renal biopsies
demonstrated typical features of diabetic nephropathy,
which included capillary basement membrane thickening,
diffuse diabetic glomerulosclerosis and nodular glomerular
sclerosis.
4.4.2. Macrovascular complications
The processes leading to atherosclerosis are complex but
a current concept called bthe response to injury hypothesisQ
considers it to be a chronic inflammatory response to some
sort of injury to the vascular endothelium. Risk factors that
predispose to atherosclerosis in the general population
include hyperlipidaemia, hypertension, cigarette smoking,
diabetes and genetic factors.
At the current time there is no documented risk of
accelerated atherosclerotic macrovascular disease associated
with CFRD. Hypertension is uncommon in the CF
population as is hypercholesterolaemia. In a study of 192
people with CF (age 21F11 years (meanFS.D.)), 4% had
elevated cholesterol and 16% had elevated triglycerides,
however, there was no relationship between abnormal lipid
concentrations and glucose tolerance [74]. Whether hyper-
lipidaemia increases the risk of cardiovascular disease in
people with CF is unknown, but may become more
important as people with CF live longer.
Glucose tolerance categories FPG,
mmol/l
2-h PG,
mmol/l
Normal glucose tolerance (NGT) b7.0 b7.8
Impaired glucose tolerance (IGT) b7.0 7.8–11.1
CFRD without fasting hyperglycaemia b7.0 z11.1
CFRD with fasting hyperglycaemia z7.0 OGTT not
necessary
FBG—fasting plasma glucose before test, 2-h PG—plasma glucose 2 h
after ingestion of 1.75 g/kg glucose.5. Diagnosis and screening
5.1. Diagnostic criteria
The oral glucose tolerance test (OGTT) is regarded as the
bgold standardQ for the diagnosis of diabetes. In 1998, theCystic Fibrosis Foundation consensus conference defined
four glucose tolerance categories for people with CF based
on the results of the 1.75 g/kg (max 75 g) OGTT; normal
glucose tolerance (NGT), impaired glucose tolerance (IGT),
cystic fibrosis-related diabetes without fasting hyperglycae-
mia (CFRD without FH) and cystic fibrosis-related diabetes
with fasting hyperglycaemia (CFRD with FH) (Table 1)
[7,75]. These are based on the American Diabetes Associ-
ation (ADA) classification [75], but the consensus commit-
tee also recognised CFRD without fasting hyperglycaemia
(FH) as a separate category. The ADA categories define
blood glucose concentrations above which intervention has
been shown to prevent diabetic complications [75], how-
ever, the level of glycaemic control required to prevent
pulmonary deterioration or reduce mortality in people with
CF has not been fully established.
5.2. Screening
As glucose tolerance in CF is defined by the oral glucose
tolerance test, this is the gold standard method for
identifying people with CFRD or IGT. However, the
consensus committee felt that it was not practical to screen
the whole CF population by this method as OGTTs are time
and resource consuming for both patients and staff [7]. The
consensus committee therefore suggested that if the random
blood glucose concentration is b7.0 mmol/l, there is no need
for further work-up unless symptoms of hyperglycaemia are
present (Table 2). However, this method may fail to detect
all people with CFRD or IGT, as the prevalence of people
identified with CFRD or IGT is greater in centres where
OGTT is routine than in those where other screening
methods are used. A compromise between approaches
which screen either all or no patients with an OGTT is to
perform OGTTs only in those identified as likely to have
glucose tolerance abnormalities through possession of one
or more of the following criteria: abnormal random blood
glucose, abnormal HbA1C, symptoms of hyperglycaemia
(Table 2) or weight loss [76]. These criteria have 92%
sensitivity and 79% selectivity in the diagnosis of CFRD
[76].
Even though the OGTT is considered the gold standard
for the diagnosis of diabetes, the OGTT result may vary
Table 2
Criteria for the diagnosis of CFRD [7]
! 2-h Fasting plasma glucose at z11.0 mmol/l during a 75g OGTT
! FPG z7.0 mmol/l on two or more occasions
! FPG z7.0 mmol/l plus casual glucose level z11.0 mmol/l
! Casual glucose levels z11.0 mmol/l on two or more occasions with
symptoms of diabetes (Table 3)
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where glucose tolerance and clinical status were monitored
in 84 people with CF, OGTT categories deteriorated in 22%
of people, but improved in 18% of people during the study
period [5]. Alteration in insulin resistance, due to change in
clinical status or drug therapies, may be responsible for
variability in OGTT category over time. A single abnormal
OGTT therefore reflects abnormal glucose handling and a
need for close monitoring, but may not alone determine
need for treatment.Table 3
Symptoms of hyperglycaemia in CF
! Unexplained polyuria or polydipsia
! Failure to gain weight despite nutritional intervention
! Poor growth velocity
! Delayed progression of puberty
! Unexplained chronic decline in pulmonary function6. Treatment of CFRD
The treatment of diabetes in the general population is
based on two general principles: first, the immediate need to
control symptoms such as polydipsia and polyuria; and
second, a long-term requirement to reduce the risk of
microvascular and macrovascular complications. In people
with CFRD there are additional unique factors to be
considered when deciding the optimal therapeutic approach
and the time to initiate treatment (Fig. 6).
6.1. When should blood glucose control be initiated in
people with CF?
People with CFRD with FH often have symptoms of
hyperglycaemia at the time of diagnosis [77], although the
diagnosis is frequently made at the time of an intercurrent
infection. In this situation the decision to treat, both to
relieve symptoms and to prevent complications is relatively
straightforward. For people with CFRD without FH or with
IGT, it is less clear whether the benefits of glycaemic control
outweigh the disadvantages of intervention.
There is some evidence that treatment may benefit people
with CF, even before CFRD has developed. Clinical status
and pulmonary function decline 2–4 years prior to the
diagnosis of CFRD with FH, perhaps due to progressive
glucose intolerance. Pre-diabetic pulmonary and clinical
decline can be reversed with insulin, suggesting a role for
early initiation of therapy as glucose intolerance develops
[54,78]. Insulin therapy also reversed decline in lung
function and weight loss in four people with long standing
CF who had normal glucose tolerance on OGTT, but
intermittent abnormal random blood glucose concentrations
[79]. Early treatment of diabetes, however, has huge
resource implications as treatment would become indicated
in around 17% of people with CF who have CFRD withoutFH and around 11% of people with CF who have IGT [10].
This highlights the need for controlled trials to define the
degree of glucose intolerance at which treatment becomes
beneficial. In the United States a 1-year randomised,
placebo-controlled trial is underway to compare the benefits
of insulin, an oral hypoglycaemic agent (repaglinide) and
placebo on muscle mass, body weight and lung function in
people with CFRD with FH and CFRD without FH. If
treatment is found to improve clinical status and lung
function in people with CFRD without FH, then similar
studies of people with IGT may also be indicated. Until
results of such studies are available, treatment is indicated
for all people with CFRD with FH but should be determined
for people with CFRD without FH and IGT on an individual
basis dependent on nutrition, pulmonary function and
symptoms (Table 3).
6.2. Type of treatment
6.2.1. Nutrition
The dietary management of CFRD is very different from
that of type 1 and type 2 diabetes (Table 4). In type 1 and 2
diabetes calorie control is important to prevent weight gain
which may worsen insulin resistance. In CFRD caloric
restriction is never appropriate, since malnutrition is
associated with stunted growth, pubertal delay, deteriora-
tion of lung function and early death. Some, but not all,
current dietary recommendations for diabetes mellitus
advise the use of low glycaemic index foods [80,81].
However, as many people with CF rely on refined sugary
foods as a source of energy, restriction of the use of these
foods may impact nutritional status. Therefore in CFRD
normalisation of blood glucose should be achieved by
balancing insulin requirements with sufficient calorie intake
[7]. Dietary recommendations for people with diabetes
mellitus encourage a reduction in saturated and polyunsa-
turated fat and a promotion of monounsaturated fat to
reduce atherosclerosis [81]. People with CFRD require a
high fat intake to maintain body weight because of
malabsorption secondary to exocrine pancreatic insuffi-
ciency. No specific recommendations have been made for
the type of fat to be eaten by people with CFRD, although
a mix would be prudent. To date there have been no reports
of people with CFRD developing macrovascular compli-
cations of diabetes on this potentially atherogenic diet.
However, in time, the recommendations on fat intake may
need to be adjusted as a small proportion of people with CF
have recently been shown to have hypertriglyceridemia and
Fig. 6. The advantages and disadvantages of blood glucose control in people with CF.
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ease could develop as people live longer [75].
6.2.2. Insulin therapy
Insulin deficiency is the primary defect in people with
CFRD, therefore insulin therapy is currently the only
recommended treatment for this condition [7]. People with
CFRD characteristically require very little basal insulin
therapy, but need supplemental insulin for meal coverage.
The CF Foundation recommends multiple daily injections
of short-acting insulin before each meal with a small dose
of long-acting insulin at night [7]. Food intake in people
with CF is often more uneven than in people with type 1 or
type 2 diabetes, with higher proportions of food being eaten
later in the day. In addition, people with CF are encouraged
to eat snacks, which are often high in kilocalories and may
receive overnight supplemental feeding. The use of short-
acting insulin provides flexibility required by this diet,
allowing the insulin dose to be adjusted to the carbohydrate
content of each meal and additional boluses to be given for
snacks or night feeds. People with CF and NGT or IGT who
develop hyperglycaemia during infective exacerbations may
require insulin therapy temporarily to restore glycemic
control, which can be withdrawn when the exacerbation is
controlled.Table 4
Comparison between the recommended dietary management type 1/type 2
diabetes and CFRD (adapted from Moran et al. [97])
Type 1/type 2 diabetes CFRD
Calories ! Calculated for maintenance,
growth or reduction diets
! 120–150% RDA
! Calories never
restricted
Carbohydrate ! Individualised ! Total intake
unrestricted
Fat ! Individualised ! High fat intake
(35–40% of
total calories)
! b10% calorie intake from
saturated fats
! Dietary cholesterol intake
b300 mg/day
Protein ! Protein reduction in presence
of diabetic nephropathy
(0.8 g/kg)
! Protein reduction
may not be
appropriate
Sodium ! Salt restriction to reduce
macrovascular complications
(b2400 mg/day)
! High sodium diet
essential
(N4000 mg/day)6.2.3. Oral hypoglycaemic agents
6.2.3.1. Agents that augment insulin release. Sulphony-
lureas enhance insulin secretion by acting on the sulphony-
lurea receptor in pancreatic h cells, stimulating insulin
release, and therefore may be useful in people with CFRD
who have residual h-cell function. A retrospective study
compared the clinical outcomes of people with CFRD
treated either with a sulphonylurea (glibenclamide) or with
insulin [82]. Diabetic treatment was initiated with gliben-
clamide and the decision to switch to insulin was based on
clinical criteria suggesting poor control, e.g. random blood
glucose above the recommended range and HbA1c in the
diabetic range. At the point of analysis HbA1c and blood
glucose concentrations were lower in the sulphonylurea-
treated group than in the insulin-treated group and there was
no difference in FEV1, FVC and weight-for-height index
between the two groups. This study implies that a subgroup
of people with CFRD have residual h-cell function and can
benefit from glycaemic control with a sulphonylurea, at
least in the short-term, delaying the need for insulin therapy.
However, there are theoretical concerns about the use of
sulphonylureas, which are able to bind to and inhibit CFTR
and could potentially interfere with new therapies designed
to improve CFTR function [83,84].
Repaglinide stimulates insulin secretion and has been
shown to increase insulin release and reduce glucose
concentrations in people with CFRD without FH [85].
In addition, repaglinide has a plasma half-life of 1 h,
which reduces the risk of between-meal or nocturnal
hypoglycaemia.
6.2.3.2. Agents that reduce insulin resistance. As insulin
resistance is not the major aetiological factor in the
development of CFRD, drugs which reduce insulin resist-
ance are unlikely to control blood glucose in CFRD when
used as a single agent. Metformin, which reduces insulin
resistance and may reduce weight gain in type 2 diabetes, is
contraindicated in CFRD due to the risk of fatal lactic
acidosis in people with hypoxia and the occurrence of
gastrointestinal side effects such as abdominal pain, nausea
and diarrhea which are unacceptable for most people with
CF. Thiazolidinediones reduce peripheral insulin resistance
[86] and improve glycaemic control in people with type 2
diabetes [87,88]. However, no studies have been performed
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limited in CFRD.
6.3. Monitoring
All people with CFRD should monitor blood glucose
levels at home. Ideally people treated with insulin should
measure blood glucose levels at least 3–4 times per day
and should be taught to adjust insulin doses accordingly. In
people with type 2 diabetes guidelines suggest that plasma
glucose should be maintained at 5.0–7.2 mmol L1 fasting
and b10 mmol L1 2 h post prandially to reduce the long-
term risk of complications [89]. However, in people with
CFRD the goals may vary dependent on clinical status. In
some people, such as individuals expected to survive more
than 5–10 years from diagnosis, even tighter control may
be desirable to minimise the risk of complications, i.e.
fasting glucose 4–6 mmol L1 and 2 h post meal glucose
4–7 mmol L1.
Glycosylated haemoglobin (HbA1c) is the standard
method for assessing long-term glycaemic control in diabetes
mellitus. Glycosylated haemoglobin levels (HbA1C) reflect
blood glucose concentrations over the preceding 2–3 months.
In type 1 DM a 1.98 mM increase in mean 24 h plasma
glucose is associated with an increase of 1% in HbA1c [90].
This relationship allows clinicians to set day to day plasma
glucose goals. In healthy subjects with normal glucose
tolerance HbA1C is b6% and in people with diabetes every
1% increase in HbA1C above this level is associated with a
30% increase in the risk of microvascular complications [91].
However, as red cell turnover may be increased in people
with CF [7,92], it is not knownwhether HbA1c is as accurate a
measure of glycaemic control in CFRD.
In the outpatient clinic people with CFRD also need to be
screened annually for microvascular complications of
diabetes. Assessment should include fundoscopy, measure-
ment of urinary albumin concentration and blood pressure
and foot examination for peripheral sensory neuropathy.
6.4. Adherence to treatment
People with CF have complex and time consuming daily
treatment regimes to manage problems including chronic
lung disease, infection, exocrine pancreatic insufficiency
and malnutrition. They spend a considerable part of each
day taking medications such as oral and/or nebulised
antibiotics, pancreatic supplements, nebulised mucolytics
agents, and vitamin supplements as well as performing daily
physiotherapy treatments [93,94]. A new diagnosis of
CFRD adds significantly to the complexity of the daily
treatment regimen, as people are required both to monitor
and to control blood glucose concentrations.
Poor adherence to therapy is a common problem in people
with chronic illness and cystic fibrosis is no exception to this.
Adherence of people with CF to physiotherapy, pancreatic
supplements and exercise is reported to be 53%, 83% and46%, respectively [95]. When people were asked their
reasons for poor adherence the most consistent answers
included busy time schedule, apathy and forgetfulness as
well as the commonly expressed beliefs bI am not as serious
as others with the diseaseQ and bI feel well without treatmentQ
[95]. People tend to decide which treatments to perform
based on their understanding of the effects and priority of
each therapy within their own regime [93]. As the duration
and complexity of treatments increases, adherence generally
decreases [96]. Although no data exists on adherence to
diabetic therapy and monitoring in people with CF, it would
surprise few clinicians if this were less than ideal.
6.5. Summary
The prevalence of CFRD and glucose intolerance has
risen dramatically over the past 20 years as survival has
increased for people with cystic fibrosis. However, although
understanding of these conditions has increased, there are
still difficult areas in the diagnosis and management of
CFRD that require further research and development.
Current guidelines are clear that people with CFRD and
fasting hyperglycaemia should be identified by random
blood glucose levels or oral glucose tolerance testing and
treated with insulin to relieve symptoms and prevent
complications. It is less clear what should happen for those
with CFRD without fasting hyperglycaemia or impaired
glucose tolerance. Oral glucose tolerance tests are currently
used to look for CFRD without FH and IGT, but these are
not performed in all centres and may not reliably predict
chronic hyperglycaemia. Where CFRD without FH or IGT
are identified, it is not known when benefits of treatment
outweigh the burden of management of a second chronic
disease and at which point treatment should be initiated.
Further studies are required to establish optimum screening
methods to identify people with CFRD without FH and IGT
and to determine whether early management of hyper-
glycaemia in these people can prevent pulmonary decline
and prolong survival.Acknowledgement
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